Sangamo Therapeutics (SGMO) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. AON
8. TMUS
9. ALHC
10. LBRX

Go back to Sangamo Therapeutics (SGMO) Misses Q2 EPS by 2c

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

August 5, 2021 4:01 PM EDT

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results.

This is an exciting time at Sangamo, as we look forward to multiple clinical catalysts over the next several quarters representing potential near-term value drivers, while we continue to advance our promising preclinical pipeline focused on the emerging areas of CAR-Tregs and transcriptional regulation, representing potential mid-term value drivers, said Sandy Macrae, Chief Executive... More